Sep 8, 2026 07:05AM
Aug 13, 2026 07:00AM
Jun 2, 2026 07:05PM
Jun 2, 2026 07:05PM
May 28, 2026 07:05AM
May 19, 2026 07:05AM
May 19, 2026 07:05AM Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
May 13, 2026 06:50AM
May 13, 2026 06:50AM
May 13, 2026 06:00AM
Mar 27, 2026 12:13AM
Mar 27, 2026 12:12AM
Mar 26, 2026 04:01PM
Mar 26, 2026 04:01PM Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
Mar 16, 2026 07:00AM
Feb 9, 2026 07:05AM
Feb 9, 2026 07:05AM
Jan 5, 2026 07:05AM
Jan 5, 2026 07:05AM
Dec 16, 2025 06:58AM
Dec 15, 2025 07:05AM InnoCare drug meets primary goal in lupus trial for Zenas partner
Dec 15, 2025 07:05AM
Nov 12, 2025 07:05AM
Oct 27, 2025 07:05AM
Oct 27, 2025 07:05AM
Oct 8, 2025 05:00AM
Oct 8, 2025 05:00AM
Sep 2, 2025 07:15AM Royalty Pharma provides up to $300 million to Zenas BioPharma for obexelimab
Sep 2, 2025 07:15AM
Sep 2, 2025 07:05AM

330,674 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All